

July 9, 2007
AnGes MG, Inc.

Completion of Targeted Number of Patient Enrollment in Phase II Clinical Trial of
NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis in Japan

Since October 2006, AnGes MG has been enrolling patients in the phase II clinical trial of NF-κB decoy oligo for the treatment of atopic dermatitis. The enrollment of the targeted number of patients for this study has recently been completed. The data from this study will be analyzed soon after completion of the evaluation period for all subjects, and the result of this study will be assessed.

NF-κB decoy oligo is being developed as a nucleic acid drug indicated for immuno-inflammatory diseases such as atopic dermatitis and rheumatoid arthritis. Of these, atopic dermatitis is a disease for which the development of a new treatment drug is eagerly awaited, since, although there are believed to be as many as 1.4 million patients in Japan, effective treatment methods have yet to be developed.

NF-κB decoy oligo, because of its characteristic of specifically suppressing transcription factors, has the potential to become an epoch-making atopic dermatitis drug that is effective and induces few adverse reactions, and therefore AnGes MG has been stepping up the clinical development of this drug in Japan.

Development in Japan of NF-κB decoy oligo used in the treatment of atopic dermatitis is being carried out in alliance with Alfresa Pharma Corporation.

<Reference>

| Field of indications | Region | Development Phase | Licensee |
|-----------------------------------|--------|----------------------------------|----------------------------|
| Atopic dermatitis | Japan | Phase II clinical trial | Alfresa Pharma Corporation |
| Psoriasis | | Preclinical | Undecided |
| Rheumatoid arthritis | | Clinical trial under preparation | Undecided |
| Osteoarthritis | | Preclinical | |
| Prevention of vascular restenosis | | Clinical trial under preparation | Goodman Co., Ltd. |